doi: 10.1038/s41598-017-11620-3.
The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome
Collaborators, Affiliations
- PMID:28947817
- PMCID: PMC5613000
- DOI: 10.1038/s41598-017-11620-3
Item in Clipboard
The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome
Silvia Vidal et al. Sci Rep..
Display options
Format
Display options
Format
Erratum in
- Author Correction: The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome.Vidal S, Brandi N, Pacheco P, Gerotina E, Blasco L, Trotta JR, Derdak S, Del Mar O'Callaghan M, Garcia-Cazorla À, Pineda M, Armstrong J; Rett Working Group.Vidal S, et al.Sci Rep. 2021 Sep 7;11(1):18146. doi: 10.1038/s41598-021-97262-y.Sci Rep. 2021.PMID:34493777Free PMC article.No abstract available.
Abstract
Rett syndrome (RTT) is an early-onset neurodevelopmental disorder that almost exclusively affects girls and is totally disabling. Three genes have been identified that cause RTT: MECP2, CDKL5 and FOXG1. However, the etiology of some of RTT patients still remains unknown. Recently, next generation sequencing (NGS) has promoted genetic diagnoses because of the quickness and affordability of the method. To evaluate the usefulness of NGS in genetic diagnosis, we present the genetic study of RTT-like patients using different techniques based on this technology. We studied 1577 patients with RTT-like clinical diagnoses and reviewed patients who were previously studied and thought to have RTT genes by Sanger sequencing. Genetically, 477 of 1577 patients with a RTT-like suspicion have been diagnosed. Positive results were found in 30% by Sanger sequencing, 23% with a custom panel, 24% with a commercial panel and 32% with whole exome sequencing. A genetic study using NGS allows the study of a larger number of genes associated with RTT-like symptoms simultaneously, providing genetic study of a wider group of patients as well as significantly reducing the response time and cost of the study.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Comparison of main coverage metrics. Average of all samples analyzed for the four different approaches. (a) Bar plots with 95% confidence interval for the four approaches. Alignment metrics: passing filter (PF) reads; percentage of PF reads that aligned to the reference sequence; and percentage of PF reads that were aligned to the reference sequence with a mapping quality of Q20 or higher signifying. (b) Tukey boxplots: Mean read depth; percentage of bases covered at C1; and percentage of bases covered at C30.
Comparison of coverage in 17 RTT-like genes. Scatter plots of average of the coverage at C1 and C30 of all samples analyzed for the four different approaches.
Statistics results for genetic diagnosis. Each columns represents different detection methodology used (SS, HCP, TSO and WES) (a) Percentage and total of families characterized and unsolved by the four different approaches. (b) Percentage of patients withMECP2,CDKL5,FOXG1, other genes with pathogenic mutations and the unsolved cases for the Sanger Sequencing (SS) and the three NGS approaches. Total of mutations found are detailed in Table S2.
Similar articles
- Pathogenic Variants inSTXBP1 and in Genes for GABAa Receptor Subunities Cause Atypical Rett/Rett-like Phenotypes.Cogliati F, Giorgini V, Masciadri M, Bonati MT, Marchi M, Cracco I, Gentilini D, Peron A, Savini MN, Spaccini L, Scelsa B, Maitz S, Veneselli E, Prato G, Pintaudi M, Moroni I, Vignoli A, Larizza L, Russo S.Cogliati F, et al.Int J Mol Sci. 2019 Jul 24;20(15):3621. doi: 10.3390/ijms20153621.Int J Mol Sci. 2019.PMID:31344879Free PMC article.
- Rett Syndrome, a Neurodevelopmental Disorder, Whole-Transcriptome, and Mitochondrial Genome Multiomics Analyses Identify Novel Variations and Disease Pathways.Aldosary M, Al-Bakheet A, Al-Dhalaan H, Almass R, Alsagob M, Al-Younes B, AlQuait L, Mustafa OM, Bulbul M, Rahbeeni Z, Alfadhel M, Chedrawi A, Al-Hassnan Z, AlDosari M, Al-Zaidan H, Al-Muhaizea MA, AlSayed MD, Salih MA, AlShammari M, Faiyaz-Ul-Haque M, Chishti MA, Al-Harazi O, Al-Odaib A, Kaya N, Colak D.Aldosary M, et al.OMICS. 2020 Mar;24(3):160-171. doi: 10.1089/omi.2019.0192. Epub 2020 Feb 27.OMICS. 2020.PMID:32105570
- Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2.Sajan SA, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, Glaze DG, Kaufmann WE, Skinner SA, Annese F, Friez MJ, Lane J, Percy AK, Neul JL.Sajan SA, et al.Genet Med. 2017 Jan;19(1):13-19. doi: 10.1038/gim.2016.42. Epub 2016 May 12.Genet Med. 2017.PMID:27171548Free PMC article.
- [Clinical features in Rett syndrome: MECP2-, CDKL5- and FOXG1- related disorders].Takahashi S.Takahashi S.No To Hattatsu. 2014 Mar;46(2):117-20.No To Hattatsu. 2014.PMID:24738188Review.Japanese.No abstract available.
- [Molecular basis of Rett syndrome: A current look].Pantaleón F G, Juvier R T.Pantaleón F G, et al.Rev Chil Pediatr. 2015 May-Jun;86(3):142-51. doi: 10.1016/j.rchipe.2015.07.001. Epub 2015 Aug 1.Rev Chil Pediatr. 2015.PMID:26239053Review.Spanish.
Cited by
- Comprehensive In Silico Functional Prediction Analysis of CDKL5 by Single Amino Acid Substitution in the Catalytic Domain.Yoshimura Y, Morii A, Fujino Y, Nagase M, Kitano A, Ueno S, Takeuchi K, Yamashita R, Inazu T.Yoshimura Y, et al.Int J Mol Sci. 2022 Oct 14;23(20):12281. doi: 10.3390/ijms232012281.Int J Mol Sci. 2022.PMID:36293137Free PMC article.
- A neuronal enhancer network upstream of MEF2C is compromised in patients with Rett-like characteristics.D'haene E, Bar-Yaacov R, Bariah I, Vantomme L, Van Loo S, Cobos FA, Verboom K, Eshel R, Alatawna R, Menten B, Birnbaum RY, Vergult S.D'haene E, et al.Hum Mol Genet. 2019 Mar 1;28(5):818-827. doi: 10.1093/hmg/ddy393.Hum Mol Genet. 2019.PMID:30445463Free PMC article.
- X chromosome inactivation does not necessarily determine the severity of the phenotype in Rett syndrome patients.Xiol C, Vidal S, Pascual-Alonso A, Blasco L, Brandi N, Pacheco P, Gerotina E, O'Callaghan M, Pineda M, Armstrong J; Rett Working Group.Xiol C, et al.Sci Rep. 2019 Aug 19;9(1):11983. doi: 10.1038/s41598-019-48385-w.Sci Rep. 2019.PMID:31427717Free PMC article.
- Rett and Rett-like syndrome: Expanding the genetic spectrum to KIF1A and GRIN1 gene.Wang J, Zhang Q, Chen Y, Yu S, Wu X, Bao X.Wang J, et al.Mol Genet Genomic Med. 2019 Nov;7(11):e968. doi: 10.1002/mgg3.968. Epub 2019 Sep 11.Mol Genet Genomic Med. 2019.PMID:31512412Free PMC article.
- Genotype-phenotype correlations of STXBP1 pathogenic variants and the treatment choices for STXBP1-related disorders in China.Kessi M, Chen B, Shan LD, Wang Y, Yang L, Yin F, He F, Peng J, Wang G.Kessi M, et al.BMC Med Genomics. 2023 Mar 7;16(1):46. doi: 10.1186/s12920-023-01474-2.BMC Med Genomics. 2023.PMID:36882827Free PMC article.
References
- Rett, A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien. Med. Wochenschr. 116, 723–726 (in German) (1966). - PubMed
- Diagnostic criteria for Rett syndrome. The Rett Syndrome Diagnostic Criteria Work Group. Ann Neurol23, 425–428 (1988). - PubMed
- Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol. 2002;6:293–297. doi: 10.1053/ejpn.2002.0612. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical